Review
Pharmacology & Pharmacy
Delphine Quatannens, Yannick Verhoeven, Peter Van Dam, Filip Lardon, Hans Prenen, Geert Roeyen, Marc Peeters, Evelien L. J. Smits, Jonas Van Audenaerde
Summary: PDAC is a leading cause of cancer related death, with urgent need for effective therapies. Aberrant activation of the Hh signaling pathway in PDAC prompts it as a possible target for treatment, despite ongoing debate on its clinical benefits.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Immunology
Azaz Ahmed, Rosa Klotz, Sophia Koehler, Nathalia Giese, Thilo Hackert, Christoph Springfeld, Dirk Jaeger, Niels Halama
Summary: This study investigated the immune features of the stroma in PDA patients, revealing a significant association of IL9 and IL18 with patient survival outcomes. IL9 was linked to an anti-tumoral cytokine network, while IL18 was associated with exhausted T cells. Patients with PDA showed higher serum levels of IL9 and lower levels of IL18 compared to healthy controls.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Vida Karimnia, Frank J. Slack, Jonathan P. Celli
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with current clinical trials showing limited improvements in patient survival. Photodynamic therapy (PDT) has emerged as a potential approach for treating pancreatic tumors based on studies indicating its effectiveness in activating photosensitizing agents in target tissues.
Review
Cell Biology
Tianyi Zhang, Yanxian Ren, Pengfei Yang, Jufang Wang, Heng Zhou
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with a high deposition of extracellular matrix (ECM) and poor prognosis. ECM proteins derived from tumor cells reduce the effectiveness of conventional cancer treatment and contribute to tumor progression and metastasis. Cancer-associated fibroblasts (CAFs) in the ECM are promising targets for novel anti-tumor interventions.
CELL DEATH & DISEASE
(2022)
Review
Oncology
Nicole Lintern, Andrew M. Smith, David G. Jayne, Yazan S. Khaled
Summary: Pancreatic cancer is highly lethal with low survival rate. The resistance to current therapies is largely attributed to the dense tissue surrounding the cancer cells. Photodynamic therapy (PDT) has shown potential in killing pancreatic cancer cells and altering the surrounding tissue.
Article
Oncology
Gokce Askan, Ibrahim Halil Sahin, Joanne F. Chou, Aslihan Yavas, Marinela Capanu, Christine A. Iacobuzio-Donahue, Olca Basturk, Eileen M. O'Reilly
Summary: The study found that the expression of CD44 and ESA in PDAC patients is related to tumor stroma type, and tumor stroma may influence recurrence patterns, but there was no significant difference among subgroups in terms of RFS and OS.
Article
Oncology
Taija Korpela, Ari Ristimaki, Marianne Udd, Tiina Vuorela, Harri Mustonen, Caj Haglund, Leena Kylanpaa, Hanna Seppanen
Summary: This study investigated the potential role of histological chronic pancreatitis findings and chronic inflammation in surgical pancreatic ductal adenocarcinoma (PDAC) specimens on disease-specific survival (DSS). The results suggest that more severe fibrosis, acinar atrophy, and chronic inflammation in the pancreatic stroma were associated with worse DSS outcomes for PDAC patients.
Review
Immunology
Sophie Liot, Jonathan Balas, Alexandre Aubert, Laura Prigent, Perrine Mercier-Gouy, Bernard Verrier, Philippe Bertolino, Ana Hennino, Ulrich Valcourt, Elise Lambert
Summary: Pancreatic cancer, especially PDAC, has a poor prognosis with low survival rates, mainly due to its dense stroma deposition and immune suppression in the TME. Research on TME composition may lead to new therapeutic targets for better treatment outcomes.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Yangyang Guo, Yu Tong, Hengyue Zhu, Yanyi Xiao, Hangcheng Guo, Lumeng Shang, Wenjing Zheng, Shumei Ma, Xiaodong Liu, Yongheng Bai
Summary: Quercetin inhibits the growth, migration, and invasion and induces apoptosis of PCCs by downregulating c-Myc expression, reducing TGF-beta1 level, and targeting SHH signaling. Quercetin treatment reduces PDA growth and metastasis in nude mouse models by decreasing SHH activity. Quercetin may be a potential candidate for PDA treatment by antagonizing SHH and TGF-beta/Smad signaling pathways.
CELL BIOLOGY AND TOXICOLOGY
(2021)
Article
Gastroenterology & Hepatology
Vikas K. Somani, Daoxiang Zhang, Paarth B. Dodhiawala, Varintra E. Lander, Xiuting Liu, Liang- Kang, Hung-Po Chen, Brett L. Knolhoff, Lin Li, Patrick M. Grierson, Marianna B. Ruzinova, David G. DeNardo, Kian-Huat Lim
Summary: The study reveals that IRAK4 drives T cell dysfunction in PDAC, making it a promising immunotherapeutic target. Combination therapy of IRAK4 inhibitors with checkpoint immunotherapy shows great potential in controlling tumors and prolonging survival.
Article
Oncology
Massimiliano Dall'Ora, Giulia Rovesti, Luca Reggiani Bonetti, Giulia Casari, Federico Banchelli, Luca Fabbiani, Elena Veronesi, Tiziana Petrachi, Paolo Magistri, Fabrizio Di Benedetto, Andrea Spallanzani, Chiara Chiavelli, Maria Carlotta Spano, Antonino Maiorana, Massimo Dominici, Giulia Grisendi
Summary: This study assessed the expression of TRAIL receptors in PDAC tumor tissue and stromal cells, finding that functional receptors were widely expressed and represented a promising treatment target. Low expression of decoy receptors in primary PDAC tumor cells was associated with a poor prognosis. A cellular-dense tumor stroma in PDAC was linked to reduced relapse-free survival.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Review
Oncology
Yang Wu, Chun Zhang, Kuirong Jiang, Jens Werner, Alexandr V. Bazhin, Jan G. D'Haese
Summary: PDAC progression is influenced by PSCs, which through interactions with PCCs and other stroma cells, establish a tumor microenvironment that promotes tumor growth, metastasis, and chemoresistance. Targeting stroma has emerged as a promising strategy for PDAC therapy, with several novel strategies proposed to intervene in this complex crosstalk.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Tanya Schild, Melanie R. McReynolds, Christie Shea, Vivien Low, Bethany E. Schaffer, John M. Asara, Elena Piskounova, Noah Dephoure, Joshua D. Rabinowitz, Ana P. Gomes, John Blenis
Summary: Metabolic adaptations and signaling events play crucial roles in promoting the survival of PDAC at the fibrotic tumor site, with a recent focus on the rewiring of NADPH production. Oncogenic KRAS has been shown to promote NADK phosphorylation, leading to increased NADK activity in PDAC cells, suggesting NADK as a potential therapeutic target for PDAC.
Article
Oncology
Li Liu, Yinliang Qi, Dake Huang, Yechuan Xu, Mingcong Li, Zhou Hong, Yanan Gu, Bo Jia, Xin Luo, Sumei Zhang, Shengquan Zhang
Summary: Pancreatic ductal adenocarcinoma (PDAC) tissues exhibit lower expression of IL-28RA compared to normal tissues. Overexpression of IL-28RA in PDAC cells reduces cell viability and inhibits cell migration, while silencing IL-28RA has the opposite effect. This study suggests that IL-28RA may play a significant role in the pathogenesis and progression of PDAC.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2021)
Article
Oncology
Jiahong Jiang, Yaping Xu, Lianpeng Chang, Guoqing Ru, Xuefeng Xia, Ling Yang, Xin Yi, Zheling Chen, Dong-Sheng Huang, Liu Yang
Summary: This study revealed the presence of driver gene mutations in PDAC stroma, indicating that the genomic features of stromal components may serve as prognostic biomarkers in resectable PDAC and may help guide a more precise treatment paradigm in therapeutic options.
FRONTIERS IN ONCOLOGY
(2021)
